Klotho overexpression improves amyloid-β clearance and cognition in the APP/PS1 mouse model of Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model and in vitro cell study
PubMed 32964663 · doi:10.1111/acel.13239
What was done
Thirteen-month-old APP/PS1 transgenic mice received intracerebroventricular injections of a lentiviral vector carrying full-length mouse Klotho cDNA to induce brain Klotho overexpression. Researchers assessed cognitive performance, amyloid-β (Aβ) pathology, synaptic and neuronal integrity, microglial phenotype transformation, and Aβ transport pathways in vivo. In vitro, the role of Klotho in Aβ transport across the blood-cerebrospinal fluid barrier was evaluated by knocking down Klotho in primary human choroid plexus epithelial cells (HCPEpiCs).
What was found
The abstract reports directional findings without numerical values, confidence intervals, or sample sizes. Brain and serum Klotho upregulation significantly reduced Aβ burden, attenuated neuronal and synaptic loss, and improved cognitive deficits in aged APP/PS1 mice. Klotho treatment significantly inhibited NLRP3 and subsequent transformation of microglia to an M2 phenotype, and also regulated Aβ transporter expression. In vitro, Klotho knockdown in HCPEpiCs significantly impaired Aβ transport.
Why it matters
This study outlines specific mechanisms—including NLRP3 inhibition, microglial phenotype modulation, and choroid plexus transport regulation—by which Klotho enhances Aβ clearance in an Alzheimer's disease model, supporting Klotho pathways as potential therapeutic targets.
Limits
This is preclinical research conducted in a transgenic mouse model and cultured cell lines, which limits direct translation to human Alzheimer's disease. The abstract does not report quantitative effect sizes, exact sample sizes, or variance measures. The long-term safety, durability, and feasibility of viral-mediated intracerebral delivery in humans were not evaluated.
Cited by
- supports Alpha-Klotho expression is associated with reduced beta-amyloid plaques in the brain.